Coronary imaging developer InfraReDx reported that the U.S. Food and Drug Administration has issued 510(k) clearance for the company to market its near-infrared (NIR) spectroscopic system for examining coronary arteries.
The InfraReDx intracoronary spectroscopy system is a fiber-optic, catheter-based device with a laser light source. The catheter is designed to perform spectroscopy of motion and blood flow in the coronary arteries, according to the Burlington, MA-based company.
By AuntMinnie.com staff writers
October 19, 2006
Related Reading
Near-infrared spectroscopy can identify vulnerable plaques in atherosclerosis, September 29, 2002
Copyright © 2006 AuntMinnie.com
![Representative example of a 16-year-old male patient with underlying X-linked adrenoleukodystrophy. (A, B) Paired anteroposterior (AP) chest radiograph and dual-energy x-ray absorptiometry (DXA) report shows lumbar spine (L1 through L4) areal bone mineral density (BMD). The DXA report was reformatted for anonymization and improved readability. The patient had low BMD (Z score ≤ −2.0). (C) Model (chest radiography [CXR]–BMD) output shows the predicted raw BMD and Z score in comparison with the DXA reference standard, together with interpretability analyses using Shapley additive explanations (SHAP) and gradient-weighted class activation maps. The patient was classified as having low BMD, consistent with the reference standard. AM = age-matched, DEXA = dual-energy x-ray absorptiometry, RM2 = room 2, SNUH = Seoul National University Hospital, YA = young adult.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/ai-children-bone-density.0snnf2EJjr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
